Media coverage about AtriCure (NASDAQ:ATRC) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AtriCure earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the medical device company an impact score of 45.110827017559 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have effected Accern’s analysis:
A number of research firms recently commented on ATRC. TheStreet raised shares of AtriCure from a “d+” rating to a “c-” rating in a research report on Friday, March 16th. BidaskClub upgraded shares of AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, March 17th. ValuEngine upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. Canaccord Genuity increased their price target on shares of AtriCure from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of AtriCure in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. AtriCure currently has an average rating of “Buy” and an average target price of $24.80.
Shares of NASDAQ:ATRC opened at $19.93 on Friday. The firm has a market cap of $693.28, a P/E ratio of -24.01 and a beta of 0.26. The company has a quick ratio of 1.87, a current ratio of 2.58 and a debt-to-equity ratio of 0.23. AtriCure has a 1-year low of $14.88 and a 1-year high of $25.18.
AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Monday, February 26th. The medical device company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.13. The firm had revenue of $46.06 million during the quarter, compared to analysts’ expectations of $45.85 million. AtriCure had a negative net margin of 15.39% and a negative return on equity of 16.74%. AtriCure’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.27) EPS. research analysts expect that AtriCure will post -0.83 earnings per share for the current fiscal year.
In related news, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Justin J. Noznesky sold 4,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $17.03, for a total transaction of $68,120.00. The disclosure for this sale can be found here. 10.00% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “AtriCure (ATRC) Getting Somewhat Favorable News Coverage, Analysis Finds” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/atricure-atrc-getting-somewhat-favorable-news-coverage-analysis-finds.html.
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.